Your Feed

Filter by
See content from
Back to the latest
Avatar
Jeff1956
Multiple Myeloma Discussion • January 15, 2025
Choosing Next Step: 2nd SCT vs. CAR-T?
AI-generated title
After two years of being in remission after a SCT my light chain numbers are creeping up. I am thinking that a second SCT would be an option. I did well with the first one and I am in pretty good health (despite the myeloma) .I believe my doctor will be recommending a CAR T cell transplant. I don’t want to use the option I would like to reserve it for the future. Any thoughts …..
Avatar
DHolcombe
Multiple Myeloma Discussion • January 14, 2025
Seeking a Myeloma Doctor in Corpus Christi?
AI-generated title
I cannot really add much to a discussion. At this time my myeloma is smoldering for about 6 years. At this time I have blood tests every six months. My Dr. Is in Houston where we moved from 2 years ago. I’m now looking for a Dr. In the Corpus Christi area.
Avatar
DaveClarke
Multiple Myeloma Discussion • January 14, 2025
My Success Story: Finding the Best Care
AI-generated title
My advice to all with MM is to find the best healthcare providers you can. Not all doctors are the same. I was diagnosed in 2018, had heart valve replacement surgery, vascular surgery, kyphoplasties, stem cell transplant, blood transfusion, 15 months of chemotherapy , and Revlimid. As of last week, my hematologist-oncologist told me the cancer is no longer a concern. Yes, it’s there but the number of cancer cells, originally at thousands per million are now at fewer than 10. Where are the best doctors? A lifetime of healthcare for my family and myself has led me to a publicly funded university hospital. The doctors spend two days a week in clinic, two days a week teaching, and one day a week researching in their field. They don’t order unnecessary tests or procedures and they will be among the first, if not the first, to learn of a cure.
Thumbnail for TP53-Mutated AML & MDS: Why Clinical Trials Are Your Best Option | Dan Link, MD | #ASH24
Playlist: ASH 2024

TP53-Mutated AML & MDS: Why Clinical Trials Are Your Best Option | Dan Link, MD | #ASH24

Video details & playlist
Thumbnail for Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24
Playlist: ASH 2024

Adding Menin Inhibitors in Combination Therapy for AML Patients | Amir Fathi, MD | #ASH24

Video details & playlist
Thumbnail for Promising Early Results from Menin Inhibitors for Treating AML | Harry Erba, MD | #ASH24
Playlist: ASH 2024

Promising Early Results from Menin Inhibitors for Treating AML | Harry Erba, MD | #ASH24

Video details & playlist
Thumbnail for Promising Results for CAR-T Cell therapy for Follicular Lymphoma | Matthew Frank, MD, PhD | #ASH24
Playlist: ASH 2024

Promising Results for CAR-T Cell therapy for Follicular Lymphoma | Matthew Frank, MD, PhD | #ASH24

Video details & playlist
Thumbnail for Promising Early Data for Improving Talquetamab Effectiveness for MM | Tarek Mouhieddine, MD | #ASH24
Playlist: ASH 2024

Promising Early Data for Improving Talquetamab Effectiveness for MM | Tarek Mouhieddine, MD | #ASH24

Video details & playlist
Thumbnail for Real World Experience of Talquetamab in R/R Myeloma Patients | Ariel Grajales Cruz, MD | #ASH24
Playlist: ASH 2024

Real World Experience of Talquetamab in R/R Myeloma Patients | Ariel Grajales Cruz, MD | #ASH24

Video details & playlist
Thumbnail for Myeloma Treatment: Teclistamab Outcomes in Academic vs. Community Settings | Adeel Khan, MD | #ASH24
Playlist: ASH 2024

Myeloma Treatment: Teclistamab Outcomes in Academic vs. Community Settings | Adeel Khan, MD | #ASH24

Video details & playlist
Thumbnail for Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD | #ASH24
Playlist: ASH 2024

Looking Back: Real-World Data on CAR-T and Bispecifics for RRMM | Natalia Neparidze, MD | #ASH24

Video details & playlist